Linganisha mbinu

	Jaribio la Kimatibabu la Awamu ya Pili la Vituo Vingi	Jaribio la Kimatibabu Lililodhibitiwa kwa Nasibu la Vituo Vingi
Nyanja	Epidemiolojia	Epidemiolojia
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	1970s–1980s (formalized in regulatory guidance; Simon two-stage design 1989)	1970s–1980s (widespread adoption for large-scale efficacy trials)
Mwanzilishi	Established through ICH and FDA regulatory frameworks; Simon two-stage design formalized by Richard Simon (1989)	Evolved from single-center RCT methodology; consolidated through landmark trials such as the MRC streptomycin trial (1948) and large cardiovascular mega-trials of the 1970s–1980s
Aina	Interventional clinical trial design	Interventional experimental design
Chanzo asilia	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2009). ICH Harmonised Tripartite Guideline: General Considerations for Clinical Studies E8(R1). ICH.	Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385
Majina mbadala	multi-site phase II trial, phase 2 multicenter study, multicenter Phase IIA/IIB trial, multisite efficacy trial	multi-site RCT, multicenter RCT, multinational randomized trial, multicenter controlled trial
Zinazohusiana	6	6
Muhtasari	A multicenter phase II clinical trial is an interventional study conducted at two or more independent clinical sites to evaluate the preliminary efficacy and safety of a new treatment in a defined patient population, following demonstrated tolerability in phase I. By pooling patients across sites, the design achieves the sample sizes needed to estimate response rates and identify promising signals before committing to the larger investment of a phase III confirmatory trial.	A multicenter randomized clinical trial (RCT) is an experimental study in which eligible participants are randomly assigned to intervention or control arms simultaneously across two or more clinical sites. By combining the rigor of randomization with enrollment from geographically or institutionally diverse centers, this design produces large samples and externally valid effect estimates that single-center trials rarely achieve. It is the regulatory gold standard for confirmatory efficacy and safety evaluation of new treatments.